Pharma Innovation Is Highest Where It Matters Most, FDA Analysis Shows
This article was originally published in Pharmaceutical Approvals Monthly
A new system of measuring innovation in new drugs proposed by analysts from FDA’s Office of Planning paints a rational picture of drug development oriented by medical need, with the greatest innovation in serious and life-threatening conditions.
You may also be interested in...
An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.
Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.
Recent submissions include what could be the fourth novel agent approved under the RTOR pilot.